ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2651

Are There Phenotypic Overlaps Between Giant Cell Arteritis Subgroups?

Berkan Armagan 1, Abdullah Yildirim 2, Alper Sarı 3, Bayram Farisoğulları 3, Emre Bilgin 3, Levent Kilic 4, Umut Kalyoncu 5, Şule Apras Bilgen 4 and Omer Karadag6, 1Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, 2Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, 3Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, 4Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 5Hacettepe University Department of Rheumatology, Ankara, Turkey, 6Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: giant cell arteritis, phenotypes and systemic vasculitides

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In parallel to the improvements in imaging, increasing data is accumulated regarding phenotypes of primary vasculitides. Giant cell arteritis (GCA) is a large vessel vasculitis encompassing cranial and extracranial arterial involvements and as well as polymyalgia rheumatica (PMR). Clinical manifestations and treatment responses may be different in the course of GCA. In this survey, we purpose to investigate the phenotypic overlap between the different vascular GCA subtypes and PMR.

Methods: We retrospectively analyzed the 55 GCA patients of the Hacettepe University Vasculitis Center (HUVAC). All clinical, laboratory, imaging and histopathological features were analyzed. The revised 2016 ACR and ACR 1990 GCA classification criteria were applied to patients diagnosed GCA according to the multidisciplinary expert group. Patients were grouped according to cranial, extracranial and PMR symptoms. Cranial GCA group comprised new headache, clinical temporal artery abnormality, visual disturbance, and jaw claudication; extracranial GCA group, limb claudication, bruits and Raynaud’s phenomenon; Polymyalgic+GCA group, bilateral shoulder/hip pain, morning stiffness and peripheral arthritis(1). Some patients had characteristics of more than one group, so the key phenotypic features of GCA were evaluated in 87 cases. Two patients were not included in any group because they did not have any symptoms according to this classification. Subgroup comparisons were done in terms of clinical features.

Results: A total of 55 GCA patients (Female/Male: 40/15) with a mean age and mean age of diagnosis patients were 73.0±9.7 and 67.7±9.2 years, respectively. Of the 43 patients (%78) met ACR 1990 classification criteria and 44 patients (%80) the revised 2016 ACR in our cohort. Temporal artery Doppler ultrasonography was applied to 36 patients and 10 (28%) of them were compatible with GCA and temporal artery biopsy was compatible in 26/36 (72%) of the patients. According to this classification 50 patients had cranial, 11 patients extracranial and 26 patients polymyagic symptoms. Of the 21 patients had characteristics features of both cranial and PMR group, 6 patients both cranial and extracranial group, and 3 patients all 3 groups. In comparison with extracranial GCA (9%) and polymyagic+GCA group (3%), cranial GCA group (40%) tends to occur more isolated. The phenotypic overlap between these groups was also illustrated in the Figure. The most common clinical signs and symptoms observed in GCA groups were shown in Table. Limb claudication (p=0.019), arterial bruits (p=0.018) and Raynaud’s phenomenon (p=0.028) were significantly higher in extracranial GCA group than other 2 groups.

Conclusion: Most of the phenotypic features were similar among GCA groups except for limb claudication, arterial bruits and Raynaud’s phenomenon in extracranial GCA group. Although there was a relationship between all groups, the cranial GCA group may exist with less clinical features.

 

References

  1. Dejaco C, et al. Rheumatology (Oxford). 2017


Table GCA cluster ACR 2019

Table. Clinical symptoms and signs in giant cell arteritis groups


Figure GCA Cluster ACR 2019

Figure. The phenotypic overlap between Giant cell arteritis subgroups


Disclosure: B. Armagan, None; A. Yildirim, None; A. Sarı, None; B. Farisoğulları, None; E. Bilgin, None; L. Kilic, None; U. Kalyoncu, UCB, 5; �. Apras Bilgen, None; O. Karadag, None.

To cite this abstract in AMA style:

Armagan B, Yildirim A, Sarı A, Farisoğulları B, Bilgin E, Kilic L, Kalyoncu U, Apras Bilgen �, Karadag O. Are There Phenotypic Overlaps Between Giant Cell Arteritis Subgroups? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/are-there-phenotypic-overlaps-between-giant-cell-arteritis-subgroups/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-there-phenotypic-overlaps-between-giant-cell-arteritis-subgroups/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology